Search

Search Constraints

You searched for: Author/Creator Bota, Daniela

Search Results

1. 154 Marrow-infiltrating lymphocytes (MILs): A novel adoptive immunotherapy for hematological and solid tumors. (10th December 2020)

2. 319 Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine. (9th November 2020)

3. 319 Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine. (9th November 2020)

4. ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM). (6th November 2017)

5. ATIM-28. PHASE II TRIAL OF AV-GBM-1 (AUTOLOGOUS DENDRITIC CELLS LOADED WITH TUMOR ASSOCIATED ANTIGENS) AS ADJUNCTIVE THERAPY FOLLOWING SURGERY PLUS CONCURRENT CHEMORADIATION IN NEWLY DIAGNOSED GBM PATIENTS. (11th November 2019)

6. ATIM-42. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: OS CORRELATIONS WITH INITIAL AND MAXIMUM CD4+T LYMPHOCYTE COUNT IN THE PERIPHERAL BLOOD. (11th November 2019)

8. CTIM-09. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: VACCINE OVERALL SURVIVAL IN BEVACIZUMAB NAIVE AND BEVACIZUMAB RESISTANT PATIENTS. (9th November 2020)

9. CTIM-26. PATIENT-SPECIFIC DENDRITIC CELL VACCINE (DC-ATA) PULSED WITH ANTIGENS FROM SELF-RENEWING AUTOLOGOUS TUMOR CELLS IN THE TREATMENT OF NEWLY-DIAGNOSED GLIOBLASTOMA: A PHASE II TRIAL. (9th November 2020)

10. CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL. (14th November 2022)